<code id='259F22938C'></code><style id='259F22938C'></style>

<acronym id='259F22938C'></acronym>

<center id='259F22938C'><center id='259F22938C'><tfoot id='259F22938C'></tfoot></center><abbr id='259F22938C'><dir id='259F22938C'><tfoot id='259F22938C'></tfoot><noframes id='259F22938C'>

<optgroup id='259F22938C'><strike id='259F22938C'><sup id='259F22938C'></sup></strike><code id='259F22938C'></code></optgroup>

<b id='259F22938C'><label id='259F22938C'><select id='259F22938C'><dt id='259F22938C'><span id='259F22938C'></span></dt></select></label></b><u id='259F22938C'></u>

~~<i id='259F22938C'><strike id='259F22938C'><tt id='259F22938C'><pre id='259F22938C'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

explore

author：fashion 2025-09-28 07:18:47 Page View：7947

Trump Campaign Event In Nevada — Ethan Miller/Getty Images

WASHINGTON — Former President Trump is back to campaigning for tying Medicare drug prices to lower prices abroad.

In Trump fashion, he claimed in a video announcement this month that he is the “only president in modern times” to take on the drug industry — and dinged President Biden directly.

advertisement

“Biden canceled my tough-on-pharma policies the moment he had a chance,” Trump said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How medical schools plan to diversify without affirmative action
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

explore

Virginia high school admissions case could be legal follow

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

The best solution to the drug shortages problem

The best solution to the drug shortages problem

AdobeDrugshortagesintheUnitedStatesareatarecordhigh.Atleast14essentialgenericcancerdrugsarecurrently

Psychedelics group wrestles with new pharma identity

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Acelyrin, a rare IPO success, stumbles in its first big test

MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir

read more